1 Min Read
March 29 (Reuters) - NOVIMMUNE SA (IPO-NOVI.S):
* SUBMITS BIOLOGICS LICENSE APPLICATION IN US FOR ITS LEAD DRUG EMAPALUMAB Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.